reports
Establishment Labs to Announce First Quarter 2024 Financial Results on...
NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13746251. The call will also...
Westwood Holdings Group, Inc. to Host First Quarter 2024 Conference Ca...
Westwood Holdings Group, Inc. to Host First Quarter 2024 Conference Call/Webcast DALLAS, April 18, 2024 (GLOBE NEWSWIRE) -- Westwood Holdings Group, Inc. (NYSE:WHG) will release its first quarter 2024 earnings after the close of the New York Stock Exchange on Wednesday, May 1, 2024. Following the release, the Company will host a live audio webcast and conference call at 4:30 pm Eastern Time (3:30 pm Central Time). To join the conference call, please register here: . After registering, you will be provided with a dial-in number containing a personalized PIN. Webcast Link: ...
Establishment Labs Announces Participation in The Aesthetic Meeting 20...
NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada. At the meeting, Dr. Caroline Glicksman, the Medical Director and an Investigator in the Motiva US IDE Study, will present an update on the clinical trial after completion of four-year follow-up. The presentation, Motiva US Core Clinical Study Update, is part of ...
- Wedbush Research
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
WDC WESTERN DIGITAL CORPORATION
UMH UMH PROPERTIES INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RWT REDWOOD TRUST INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
MXL MAXLINEAR INC
MU MICRON TECHNOLOGY INC.
MFA MFA FINANCIAL INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
AXTI AXT INC.
ABR ARBOR REALTY TRUST INC.
WD WALKER & DUNLOP INC.
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
RC READY CAPITAL CORPORATION
COOP MR. COOPER GROUP INC.
SMCI SUPER MICRO COMPUTER
PFSI INC.
RKT PENNYMAC FINANCIAL SERVICES INC.
GHLD ROCKET COMPANIES
MRVL GUILD HOLDINGS
STX MARVELL TECHNOLOGY INC
UWMC SEAGATE TECHNOLOGY HLDGS PLC
GFS UWM HLDGS CORP
EWTX GLOBALFOUNDRIES INC
CAVA EDGEWISE THERAPEUTICS INC
CAVA GROUP INC
- Brian Violino
- Henry Coffey
- Jay McCanless
UMH UMH PROPERTIES INC.
RWT REDWOOD TRUST INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
MFA MFA FINANCIAL INC.
ABR ARBOR REALTY TRUST INC.
WD WALKER & DUNLOP INC.
RC READY CAPITAL CORPORATION
COOP MR. COOPER GROUP INC.
PFSI PENNYMAC FINANCIAL SERVICES INC.
RKT ROCKET COMPANIES
GHLD GUILD HOLDINGS
UWMC UWM HLDGS CORP
Amundi and Victory Capital announce plan to establish a strategic part...
PARIS & SAN ANTONIO--(BUSINESS WIRE)-- Amundi and Victory Capital (Nasdaq: VCTR) are announcing today that they have signed a Memorandum of Understanding to combine Amundi US into Victory Capital, for Amundi to become a strategic shareholder of Victory Capital, and to establish long-term global distribution agreements. The proposed transaction would create a broader US investment platform for clients of both firms, provide Amundi with access to a wider set of US-managed capabilities, and expand worldwide distribution for Victory Capital. The proposed transaction would benefit clients of both...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at th...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced present...
Vishay Precision Group Announces Date for Its First Quarter Fiscal 202...
Vishay Precision Group Announces Date for Its First Quarter Fiscal 2024 Earnings Conference Call MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will release its financial results for the first quarter of fiscal 2024 before the opening of the market on Tuesday, May 7, 2024. Ziv Shoshani, chief executive officer, and Bill Clancy, chief financial officer, will host a conference call that day (Tuesday, May 7, 2024) at 9:00 a.m. U.S. eastern time. To access the conference call, interested p...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on ...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and provide a business ...
Victory Capital Reports March 2024 Total Client Assets
SAN ANTONIO--(BUSINESS WIRE)-- Victory Capital Holdings, Inc. (NASDAQ: VCTR) (“Victory Capital” or the “Company”) today reported Total Assets Under Management (AUM) of $170.3 billion, Other Assets of $5.1 billion, and Total Client Assets of $175.5 billion, as of March 31, 2024. For the month of March, Average Total AUM was $167.6 billion, average Other Assets was $5.3 billion, and average Total Client Assets was $172.9 billion. For the first quarter, the Company reported long-term AUM net flows of -$1.0 billion. Victory Capital Holdings, Inc. Total Client Assets (unaudited; in ...
Westwood Launches First Exchange-Traded Fund: Westwood Salient Enhance...
Westwood Launches First Exchange-Traded Fund: Westwood Salient Enhanced Midstream Income ETF (MDST) A Solution Focused on Generating High Monthly Distributable Income DALLAS, April 09, 2024 (GLOBE NEWSWIRE) -- (WHG), a publicly-traded investment management boutique and wealth management firm, today launched the Westwood Salient Enhanced Midstream Income ETF (NYSE: MDST). The fund is the first . MDST seeks to deliver current income and capital appreciation by investing in midstream energy companies, defined as companies and master limited partnerships (MLPs) that gather, transp...
Macrogenics Inc: 1 director
A director at Macrogenics Inc sold after exercising options/sold 51,395 shares at 15.549USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data ...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data, including safety and preliminary efficacy, by May 31Company plans to provide additional clinical data – including rPFS – in the Fall of 2024 ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, devel...
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Con...
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024. Presentation details: Date:Wednesday, April 10th Time:8:00-8:40 AM ET Webcast:, or on the Events section of the company’s Inv...
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for...
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the initiation of the ENGAGE Phase 3 trial of solriamfetol, an investigational treatment for binge eating disorder (BED) in adults. ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomi...
- Wedbush Research
TRNO TERRENO REALTY CORPORATION
TRIP TRIPADVISOR INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
NCMI NATIONAL CINEMEDIA INC.
IMAX IMAX CORPORATION
EXPE EXPEDIA GROUP INC.
CNK CINEMARK HOLDINGS INC.
ABR ARBOR REALTY TRUST INC.
WD WALKER & DUNLOP INC.
BLDR BUILDERS FIRSTSOURCE INC.
BKNG BOOKING HOLDINGS INC.
COOP MR. COOPER GROUP INC.
RH RESTORATION HARDWARE INC.
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
PFSI PENNYMAC FINANCIAL SERVICES INC.
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
YOU CLEAR SECURE INC
- Brian Violino
- Henry Coffey
- Jay McCanless
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-...
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Le...
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient ...
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients 77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI) Depression and anxiety were experienced by...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.